Venous thromboembolism (VTE) is a potentially life-threatening medical condition. Pregnancy induces a hypercoagulable state with an increase in coagulation factors and a decrease in natural anticoagulants, which increases the risk of deep-vein thrombosis (DVT) and pulmonary embolism (PE) in ~0.5 -2.2 per 1 000 pregnancies.
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Venous thromboembolism (VTE) is a potentially life-threatening medical condition. Pregnancy induces a hypercoagulable state with an increase in coagulation factors and a decrease in natural anticoagulants, which increases the risk of deep-vein thrombosis (DVT) and pulmonary embolism (PE) in ~0.5 -2.2 per 1 000 pregnancies. [1] Furthermore, the puerperium is the time of maximal risk of pregnancy-associated VTE.
The use of thromboprophylaxis in patients at risk of VTE is of proven benefit, with low-molecular-weight heparin (LMWH) reducing VTE risk in medical and surgical patients by 60% and 70%, respectively. [2] No adequately powered randomised controlled trials have investigated the efficacy and safety of pharmacological prophylaxis in pregnancy and the puerperium. However, VTE pharmacological prophylaxis is advocated by both international [3] and local guidelines, [4] and is regarded as the standard of care in the appropriate patient.
The absolute risk for VTE in pregnancy is low, and risk stratification is required to determine which patients would benefit from thromboprophylaxis. [3] There is a paucity of data on VTE risk stratification and thromboembolism prophylaxis in South African (SA) patients in general, [5] and specifically during pregnancy and the puerperium.
Objectives
To evaluate local practices with regard to VTE risk stratification and thromboembolism prophylaxis during pregnancy and the puerperium.
Methods
This study was a sub-analysis of patients who participated in the SAVE global study, the primary objective of which was to estimate the proportion of women at risk of VTE during pregnancy and the postpartum period among all women attending prenatal and/ or obstetric centres. Secondary objectives included determining the proportion of women at risk receiving an effective type of VTE prophylaxis according to the American College of Chest Physicians [6] and/or Royal College of Obstetricians and Gynaecologists (RCOG) [3] guidelines, analysing factors that drive the decision to provide This open-access article is distributed under Creative Commons licence CC-BY-NC 4.0.
Assessment and management of venous thrombo embolism risk during pregnancy and the puerperium (SAVE):
The South African cohort RESEARCH prophylaxis, and determining the overall proportion of patients receiving mechanical v. pharmacological prophylaxis. The criteria for VTE risk assessment (high risk, intermediate/moderate and lower risk) are set out in Table 1 . [3] Study design and setting
The SAVE study was a non-interventional, cross-sectional descriptive study conducted in 18 countries from December 2014 to October 2015. The primary study [7] has been reported, and this article describes the SA cohort.
Criteria for selection of doctors and patients
A master list of doctors from SA was generated by the Sanofi clinical trials department. The list was based on the potential of the participating doctors to recruit the appropriate patients within the study timelines, and we attempted to obtain representation from both the SA public and private healthcare sectors. We then contacted each doctor on the master list and asked them to complete a site feasibility questionnaire to indicate their interest in the study and the number of patients they could potentially contribute to it.
Patients selected [7] were women aged >18 years with objectively confirmed pregnancy, visiting for the first prenatal consultation or any other consultation during pregnancy, with an underlying medical condition, with/without the need for pre-partum hospitalisation for medical reasons, and who were willing to participate. Patients excluded were women with a VTE event in the preceding 4 months or those using concurrent antithrombotic therapy for other medical reasons.
Information collected [7] Information was collected via participating doctors' questionnaires and case report forms and included patient demographics, history, reason/s for consultation and VTE risk stratification. Information on the doctors included demographics, specialty, and their evaluation of VTE risk stratification and management.
Sample size [7] A detailed description of the statistical analysis can be found in the primary paper. [7] The local sample size was selected based on numbers needed in the original SAVE study.
Ethical considerations
The study received approval from the local ethics committees (Pharma-Ethics and the University of Pretoria ethics committee), and the study participants gave signed informed consent.
Results

Physician characteristics
There were six study sites staffed with 6 medical doctors participating in the study. The majority of the doctors were aware of the existence of guidelines for VTE (83.3, 5/6) with 3 following the guidelines. Reasons for not following the guidelines included lack of time and 'other' . The questionnaire did not allow for description of the local guideline, which may have been interpreted as a local institutionally based guideline or national guideline.
Patient disposition and characteristics
Of a total of 224 patients screened, 220 were considered eligible to participate in the study. The 4 screen failures were based on the participating doctor's decision. Of the six study sites, 50% were public sector sites and 50% private sector sites. A total of 90 and 130 patients were recruited from the private and public sector sites, respectively. ; readmission or prolonged admission (≥3 days) in the puerperium; any surgical procedure in the puerperium other than repair of perineum; medical comorbidities, e.g. cancer, heart failure, active systemic lupus erythematosus, inflammatory bowel disease or inflammatory polyarthropathy, nephrotic syndrome, type 1 diabetes mellitus with nephropathy, sickle cell disease; current intravenous drug user Intermediate/moderate risk (≥2 risk factors) and lower risk (<2 risk factors) Age >35 years; parity ≥3; smoker; elective caesarean section; family history of VTE; low-risk thrombophilia; gross varicose veins; current systemic infection; immobility, e.g. paraplegia, pelvic girdle pain with reduced mobility, long-distance travel; current pre-eclampsia; multiple pregnancy; preterm delivery in this pregnancy (<37 weeks); stillbirth in this pregnancy; mid-cavity rotational or operative delivery; prolonged labour (>24 hours); postpartum haemorrhage VTE = venous thromboembolism; LMWH = low-molecular-weight heparin.
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Of the 220 patients entered into the study, 172 (78.2%) were black. The mean (standard deviation (SD)) age of the cohort was 29.4 (5.9) years (Table 2) . Thirty-two patients (14.5%) were HIV-positive, and 98 (44.5%) were obese (Table 3 ). In the majority of cases (n=169, 76.8%) the consultation was a routine visit ( Table 4) .
The majority of consultations were during pregnancy (n=183, 83.2%), specifically the third trimester (n=89, 40.5%), with a mean (SD) gestation of 26.8 (9.1) weeks.
Proportion and intensity of VTE risk
According to the participating doctors, 126/220 patients (57.2%) were at risk of VTE during pregnancy and postpartum (information was missing for 1 woman during the postpartum period); of the pregnant patients, 94/127 (74.0%) were at risk, and of those in the in the puerperium, 32/126 (25.4%) were at risk. When the risk was stratified by intensity, 9/32 postpartum patients (28.1%) were at high risk. VTE risk stratification was missing for one patient. Table 5 sets out the risk stratification for women at risk of VTE during pregnancy and postpartum.
VTE prophylaxis
Of the 126 women at risk, 104 (82.5%) (95% confidence interval (CI) 74.08 -88.16) were prescribed thromboprophylaxis, during pregnancy in 75/94 cases (79.8%) (95% CI 70.25 -87.37) and Table 6 describes the patients receiving thromboprophylaxis during pregnancy and the puerperium. During pregnancy and before delivery. Some patients had multiple reasons for non-prescription of thromboprophylaxis. The major reason for not prescribing thromboprophylaxis during pregnancy and before delivery was the fear of bleeding (n=24, 40.7%), followed by a perception of increased risk associated with thromboprophylaxis (negative benefit/risk ratio) (n=15, 25.4%). Fourteen of 16 patients (87.5%) received pharmacological thromboprophylaxis, specifically LMWH, during pregnancy and before delivery. Two patients received only mechanical thromboprophylaxis during pregnancy and before delivery. Table 7 details VTE prophylaxis during pregnancy and delivery.
During the puerperium. One hundred and four patients (96.1%) received prophylaxis during the puerperium (this figure includes those who had been at risk during pregnancy), with only 4 (3.8%) not receiving therapy. The reasons for not receiving therapy were 
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'No available proof ' (n=2), i.e. the investigator does not consider thromboprophylaxis in pregnancy as 'valid' and 'recognised' , fear of bleeding (n=1), and perception of increased risk associated with thromboprophylaxis (negative benefit/risk ratio) (n=1). Seventy patients (70.0%) received pharmacological thromboprophylaxis and 30 (30.0%) both pharmacological and mechanical prophylaxis in the puerperium. LMWH was the most commonly used pharmacological prophylaxis (n=87, 87%), with new oral anticoagulants (NOACs) (non-vitamin K antagonists) in 8 (8%). Of note, 34 (34%) received prophylaxis for only 5 -10 days after caesarean section. Table 8 details VTE prophylaxis during the puerperium.
Risk factors determining prophylaxis
SA Asian women (n=24) were more likely to be perceived to be at risk of developing VTE than white women (Wald χ 2 p-value 0.0316; odds ratio estimate 13.143; 95% CI 1.255 -137.667). Drivers for VTE thromboprophylaxis included pre-eclampsia, caesarean delivery and immobility (Table 9 ).
Discussion
Drivers for VTE thromboprophylaxis included pre-eclampsia, caesarean delivery and immobility. The relatively low use of VTE thromboprophylaxis during pregnancy is concerning. Clinicians cited fear of bleeding and perception of an increased risk associated with thromboprophylaxis (negative benefit/risk ratio) during pregnancy as the major deterrents to using pharmacological agents during pregnancy. However, mechanical thromboprophylaxis was underutilised, with only 2 patients receiving this during pregnancy. The RCOG Green-top guideline [3] recommends the use of mechanical thromboprophylaxis for patients with a contraindication to LMWH. This is a grade D recommendation based on relatively less robust data. Mechanical thromboprophylaxis has no bleeding risk, and clinicians would therefore have been expected to use it in patients at high risk of bleeding diathesis. Non-availability of DVT stockings in the public health sector may have contributed to this finding.
Research is required to determine how clinicians stratify bleeding risk during pregnancy.
The majority of the patients received VTE prophylaxis for only 5 -10 days after delivery, which is not aligned with current guide lines. According to the RCOG Green-top guideline, [3] thromboprophylaxis should be continued for 6 weeks in high-risk women and for 10 days in those at intermediate risk. Short duration of thromboprophylaxis may result in a residual risk of VTE, with potential catastrophic consequences. Unfortunately the study did not elucidate the reasons for inadequate duration of thromboprophylaxis.
LMWH was the preferred pharmacological agent for VTE prophylaxis. Only 8% received a non-vitamin K oral anticoagulant in the postpartum period. LMWH is considered the standard of care locally and internationally. Non-vitamin K antagonists were used in the minority of patients, probably because the public sector sites did not have access to these drugs and they should not be used during pregnancy and lactation [3] because their safety and efficacy during this period have not been established.
Snyman and Potgieter [8] investigated the VTE risk profile and thromboprophylaxis in 109 patients undergoing gynaecological surgery in a single-centre academic unit. Only 5% of study participants received the correct VTE prophylaxis. Direct comparisons between their study [8] and the present study cannot be made because they evaluated VTE in different groups of patients, i.e. gynaecological v. obstetric, and the doctors prescribing prophylaxis were unaware that they were being audited. Nevertheless, the present study had a higher proportion of patients receiving appropriate therapy. The clinicians who took part in the study are senior clinicians working in clinical trial sites and are therefore likely to be up to date with respect to guidelines. Furthermore, the study itself and the knowledge that they would be audited may have motivated them to better understand VTE risk stratification and management. These clinicians probably reflect the current best practices in SA.
HIV infection is increasingly being considered a prothrombotic state. [9] The prevalence of HIV-positive patients in this study (14.5%) 
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is lower than the prevalence of ~29.7% in antenatal clinics in SA.
[10]
These figures may differ because the antenatal clinic data only include public sector patients. Our cohort had a high prevalence of obesity, with 98 women (44.5%) having a body mass index >30 kg/m 2 . SA has the highest prevalence of obesity in sub-Saharan Africa, which may be attributed in part to rapid socioeconomic transition. [11] Obesity complicates the use of pharmacological agents, with the possibility that altered pharmacokinetics may require dose adjustments. In addition, obesity itself is a risk factor for VTE.
Study limitations
The study was limited by the small sample of clinical trial sites (six sites) and the fact that the participating doctors were relative experts. Owing to the shortage of obstetricians and gynaecologists in SA, the majority of patients are treated by non-specialists whose adherence to guidelines may be less than ideal. The study may not reflect management of VTE risk during pregnancy and the puerperium in SA as a whole, which is dominated by a public sector characterised by skill shortages and high patient numbers. The study sites were all urban centres and therefore do not reflect rural practice. Despite its limitations, however, the study provides valuable insights into VTE risk stratification and thromboprophylaxis.
Conclusions
The doctors participating in the study were in general aware of VTE risk during pregnancy and the puerperium. However, VTE thromboprophylaxis during pregnancy could be improved. Clinicians cited fear of bleeding and a perception of increased risk associated with thromboprophylaxis (negative benefit/risk ratio) as reasons for not using pharmacological thromboprophylaxis during pregnancy, but still underused mechanical thromboprophylaxis. Patients in this study did not receive the recommended duration of thromboprophylaxis. Further research and novel methods are required to improve VTE prophylaxis during pregnancy and the puerperium.
We suggest the development of SA guidelines for the management of VTE risk during pregnancy or adoption of the current international guidelines (e.g. RCOG). Education of all relevant healthcare workers is needed regarding VTE risk stratification and management during pregnancy.
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